The possibility of prenatal diagnosis of CAH by steroid determinations and HLA typing i n arrmiotic f l u i d and the knowledge t h a t Dexamethasone (Dexa) crosses the placental barrier induced attempts on prenatal treatment of CAH g i r l s by giving the m t h e r s Dexa during pregnancy. The question i s when t o start trea-t. Androgens start to a c t a t week 8 of gestation, but it is still under discussion whether the f e t a l adrenals are under hypphyseal control before week 20.
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W e treated the m t h e r of a severely v i r i l i z e d CAH g i r l during her second pregnancy. W e gave Dexa (0.5 q / d ) from week 12 to week 15, stopped f o r 7 days before amniocentesis, and then continued t r e a t n w t u n t i l delivery. The fetus was diagnosed t o be fe-M e and hmzygous f o r CAH. Pregnancy and delivery were uncomplicated. The treated g i r l was v i r i l i z e d t o the same degree as her untreated s i s t e r ; hrnever,clitorcgnegaly was markedly l e s s developed (2an i n length vs 4an i n the untreated child). Adrenal steroids were elevated slightly i n d i l i c a l vein and artery, but highly i n plasm a t day 5 of l i f e . lie see three possible explanations for the f a c t t h a t v i r i l i z ation was influenced not qualitatively but only quantitatively by prenatal treabwnt: 1. the dose of Deva m y have been too low; 2. t r e a m n t m y have started too l a t e ; 3 . the activity of the f e t a l adrenals possibly is not influenced by Dexa a t the tin%? when early steps of v i r i l i z a t i o n take place. A blood spot (ES) assay was developed for use in infants to supplement plasma/saliva 17P assays used to monitor older CAH children. 17P recovery from a 6 rnm blood disc immersed inethml, eluted with buffer and solvent extracted was >95%. A rnaynetised solid-phase antiserum and 1 Z 5~-t r a c e r was used as in the routine 17P assay. Sensitivity was 1.5 py/tube (0.5 nmol/L). S i m u l w plasma, saliva and B S samples were collected 1-2 hrly for 12-2hr from treated patients. Profiles of 17P in a l l 3 matrices was identical, whatever the control (r=0.99). Weekend profiles of ES and saliva 17P in % r n p !~ collected a t home are shown in the 
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i n i c a l f e a t u r e s of t h e Cushing syndrome. R e s u l t s of biochemical s t u d i e s ( i n f o u r p a t i e n t s t e s t e d ) suggested t h e presence of an autonomously f u n c t i o n i n g a d r e n o c o r t i c a l neoplasm. However, r a d i o l o g i c examination of t h e a d r e n a l s d i d n o t show an a d r e n a l tumor. The f i v e p a t i e n t s underwent c u r a t i v e b i l a t e r a l t o t a l adrenalectomy and d i d n o t manifest t h e Nelson syndrome p o s t o p e r a t i v e l y (follow-up, 0.5-22 y e a r s ) . The a d r e n a l pathol o g i c f i n d i n g s i n t h e s e p a t i e n t s were s i m i l a r . Gross f i n d i n g s included:
1) decreased, normal, o r s l i g h t l y i n c r e a s e d t o t a l gland weight; 2) s t u d d i n g of t h e e x t e r n a l and c u t s u r f a c e s by s m a l l ( < 4 rmn) b l a c k , brown, dark-green, r e d , o r ( r a r e l y ) yellow nodules; and 3) c o r t i c a l atrophy and d i s o r g a n i z a t i o n of t h e normal zonation between t h e nodules.
Microscopically, t h e nodu l e s were composed predominantly of e n l a r g e d , g l o b u l a r , c o r t i c a l c e l l s w i t h g r a n u l a r e o s i n o p h i l i c cytoplasm t h a t o f t e n contained l i p o f u s c i n . Twenty-six s i m i l a r c a s e s have been r e p o r t e d o r communicated t o us.
Findings i n t h e s e p l u s our f i v e c a s e s i d e n t i f y a s p e c i a l type of a d r e n o c o r t i c a l pathology a s s o c i a t e d w i t h Cushing syndrome, f o r which we s u g g e s t t h e name "primary pigmented nodular a d r e n o c o r t i c a l d i s e a s e . "
There were t h r e e i n s t a n c e s of f a m i l i a l involvement. We r e p o r t a 10 y e a r o l d female w i t h Cushing's disease w i t h r e c u r r e n t disease 5 y r s a f t e r successful p i t u i t a r y i r r a d i a t i o n . A t presentation, bone age, s k u l l f i l m s , head CT and v i s u a l f i e l d s were a l l normal. Basal serum F, u r i n a r y 17-OHCS, f r e e c o r t i s o l (F), and 6 % -h y d r o c o r t i s o l (66-OHF) were elevated. Serum F lacked c i r c a d i a n v a r i a t i o n and was p a r t i a l l y suppressed by h i g h dose dexamethasone (dex). She received p i t u i t a r y i r r a d i a t i o n w i t h a cumulative dose o f 4,000 rads over a 1 month period. Serum F, 17-OHCS, 66-OHF, u r i n a r y f r e e F r e t u r n e d t o normal, growth v e l o c i t y improved, and puberty ensued w i t h menarche o c c u r r i n g 3 y r s a f t e r i r r a d i a t i o n .
However, l a c k o f d i u r n a l v a r i a t i o n o f F p e r s i s t e d . Despite radiotherapy, f i v e years l a t e r she developed c l i n i c a l and biochemical evidence o f m i l d r e c u r r e n t Cushing's disease. Bone age, head CT, v i s u a l f i e l d s , and TRH, LHRH and L-DOPA/glucagon t e s t i n g were a l l normal. Morning c o r t i s o l , 17-OHCS, and 68-OHF were e l e v a t e d and were p a r t i a l l y suppressed o n l y a f t e r h i g h dose dex. The 8:00 PM ACTH l e v e l was e l e v a t e d t o 40 pcg/ml.
A f t e r o v i n e CRF a d m i n i s t r a t i o n t h e maximum ACTH response was 46 pcg/ml; t h e ACTH c o n c e n t r a t i o n i s increased and t h e absent ACTH response t o CRF i s abnormal. I n p a t i e n t s w i t h Cushing's disease t r e a t e d w i t h radiotherapy, t h e ACTH resoonse t o CRF s t i m u l a t i o n mav n o t be r e l i a b l y compared t o t h a t o f ' n o r m a l c o n t r o l s .
Conclusion: Therefore Cushing's disease may r e c u r d e s p i t e successtul p i t u i t a r y i r r a d i a t i o n . This,suggests a hypothalamic CRF producing l e s i o n as t h e primary l e s i o n I n Cushing s disease.
BROMOCRIPTINE TREATMENT FOR CUSHING 1 22 DISEASE UNDER THE FORM OF INTERMEDIATE:
---LOBE DISEASE, Thomas E. Romer, Anna Wolskal J e r z y Klimaszewski. Child's Health C e n t e r , Warsaw, Poland.
In two c a s e s of Cushinq d i s e a s e diaqnosed on the b a s i s of cli---nical symptoms and laboratory findings with abolished circadian cortisol rhythm the following t e s t were performed: I. V. bolus TRH and LH-RH t e s t s with serum ACTH radioimmunoassay and I.V. infuion cortisol suppression t e s t according to Fehm e t al..
I n female patient A. P. , 11 y e a r s old, a brisk i n c r e a s e of serum ACTH after LH-RH was noticed, i n male patient G. C . , 17 y e a r s old, i n c r e a s e of serum ACTH a f t e r TRH was stated. On the bas i s of this t e s t s an "intermediate lobe disease" was diagnosed.
Additionaly i n patient G . C. a paradoxical i n c r e a s e of ACTH during the cortisol infusion, was observed. On the treatment / P a rlode1 7 mg/day/ a prompt r e l e a s e of symptoms and a significant growth acceleration i n both patients w e r e observed. The grow-:h r a t e i n patient G. C. before treatment was 0 , 8 and during t r e a tment 3 , l c m /~e a r and in patient A.P. 
